Sumitomo Dainippon Pharma Co., Ltd. Patent applications |
Patent application number | Title | Published |
20160129000 | METHOD OF TREATMENT FOR MENTAL DISORDERS - The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D | 05-12-2016 |
20160122319 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE - The present invention provides a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof with high selectivity for dopamine D | 05-05-2016 |
20160114019 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 04-28-2016 |
20160106719 | Transplantation Adjuvant in Cell Therapy Using Neural Progenitor Cells - The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient. | 04-21-2016 |
20160045582 | CONJUGATE VACCINE USING TRIMMING FUNCTION OF ERAP1 - The present invention provides a compound represented by the formula (1): | 02-18-2016 |
20150238587 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 08-27-2015 |
20150210640 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE - A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; R | 07-30-2015 |
20150087830 | PROCESS OF A QUATERNARY AMMONIUM SALT - The present invention relates to a novel process for preparing quaternary ammonium salt derivatives. | 03-26-2015 |
20150080321 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 03-19-2015 |
20140371236 | AGENT FOR TREATMENT OF SCHIZOPHRENIA - The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,23,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in said method. | 12-18-2014 |
20140356292 | IN VIVO SCREENING METHOD OF THERAPEUTIC AGENT FOR MEMORY/LEARNING DYSFUNCTIONS BY SCHIZOPHRENIA - A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. | 12-04-2014 |